Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
Luca AfferiMartin SpahnStefanie HayozRäto T StrebelSacha I RothschildHelge SeifertBerna C ÖzdemirBernhard KissPhilipp MaletzkiDaniel EngelerGregory WirthBoris HadaschikIlaria LuccaHubert JohnAndreas SauerMichael MüntenerLukas BubendorfMartina SchneiderJana MusilovaUlf PetrauschRichard Cathomasnull nullPublished in: BJU international (2024)
This study supports the surgical safety of RC and PLND following neoadjuvant chemo-immunotherapy in patients with MIBC. The extent and completeness of protocol-defined PLND varies between patients, highlighting the need to communicate and monitor the surgical template.
Keyphrases
- rectal cancer
- locally advanced
- lymph node
- neoadjuvant chemotherapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- robot assisted
- squamous cell carcinoma
- prognostic factors
- prostate cancer
- radiation therapy
- drug delivery
- patient reported outcomes
- quality improvement